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Background
We report the effective and safe use of subcutaneous
immunoglobulin (SCIG) therapy in a patient who suffered
stroke following replacement intravenous immunoglobulin
(IVIG) infusions for common variable immune deficiency
(CVID) at age 28 years.
Methods
CVID is one of the 6 FDA-approved uses for IVIG, and is
required lifelong in these patients. Systemic adverse reac-
tions occur in approximately 2-6% of infusions 1, while
thrombotic events are very rare. A Therapeutic dilemma
arose when our patient had a stroke after an IVIG
infusion.
After the stroke, our patient’s IgG level fell to 1.17 g/L,
resulting in recurrent pneumonia. Cautious doses of IVIG
were restarted and the patient remained on warfarin.
These were tolerated well for 13 years. With the introduc-
tion of higher concentrations of IgG available for subcuta-
neous administration, we transitioned the patient to SCIG
since it offered many advantages. The preparation was tol-
erated well by the patient, resulted in therapeutic trough
levels, and was effective at preventing infection. It is also
associated with a lower risk of thrombotic complications
including stroke theoretically since this is extremely rare,
related to the even physiologic nature of serum IG levels,
without marked increases in levels following the adminis-
tration of the SCIG preparation 2.
Results
The patient was cautiously continued on IVIG therapy 7
months after the stroke, with modest doses initially of 20g
in 250mL solution q4 weeks (goal trough IgG 5-7 g/L).
This dose was effective and tolerated well and it was gra-
dually titrated to higher trough levels 9 years later. With
known and theoretical advantages of SCIG therapy, the
patient achieved therapeutic trough IG level of 9.5 g/L,
and did not have any further thrombotic events or other
systemic reactions. The patient continues on q3-4-weekly
SCIG infusions that are both safe and effective. This ther-
apy may also offer significant Quality of life (QOL) advan-
tages to the patients and their families.
Conclusions
We report a CVID patient who had a cerebrovascular acci-
dent following an IVIG infusion. He was successfully
restarted on IVIG therapy while on warfarin and then
switched to SCIG, which he has tolerated well.
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